Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases. In line with this strategy two of Inventiva’s compounds, lanifibranor and odiparcil, have received orphan drug designation by the FDA and EMA and now benefit from regulations which support accelerated development.
Over the years Inventiva has developed a recognized expertise in the field of nuclear receptors, transcription factors and epigenetic modulation, which are sources of innovative therapeutic targets. We validate our targets in house and use our pharma standard research platform, including biology teams, screening equipment, medicinal chemistry, ADME and pharmacology resources, as well as its our own library of 240,000 compounds to develop a regular flow of drug candidates. The product pipeline is rich and diversified with two products, lanifibranor (IVA337) and odiparcil (IVA336), at clinical stage, two research partnerships with AbbVie and Boehringer Ingelheim, as well as several innovative projects at preclinical stage.
Inventiva is a public company traded on Euronext Paris.